Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

The case is pending in the U.S. District Court for the District of New Jersey and is captioned Moon v. Novo Nordisk A/S, et al., No. 25-cv-00713. Why was Novo Nordisk Sued for Securities Fraud?

Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...

The case, filed in the U.S. District Court for the District of New Jersey under the title Moon v. Novo Nordisk A/S, No. 25-cv-00713, alleges that the company and its key executives committed ...

[email protected] 844-916-0895 Novo Nordisk A/S (NVO) Securities Class Action: The suit, filed in the U.S. District Court for the District of New Jersey and captioned Moon v. Novo Nordisk A/S ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has determined the shortage of Wegovy® and Ozempic® is resolved. The FDA's assessment confirms the U.S. supply of these ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.